Wednesday, August 5, 2026

AFFF Surge Sharpens a 79-Filing Docket

These event summaries are AI-generated and still in beta. Pending our full analytics build-out, please verify critical dates independently. Spot something off? Let us know.

We tracked 79 new filings yesterday. Hair Relaxer and AFFF supplied 36, but AFFF produced the sharper turn, jumping from one personal-injury filing to 17. Ozempic also accelerated as JPML's Aug. 3 statistics put that docket at 3,928 pending actions.

The AFFF Products Liability Litigation (2873) added 17 personal-injury cases. Environmental Litigation Group PC filed 14 and Napoli Shkolnik filed two. The concentrated intake arrived while former Chief Judge Margaret B. Seymour works through roughly 8,000 documentation-based dismissal requests referred by Judge Richard M. Gergel on June 15. The referral calls for a report and recommendation within 90 days, placing the next procedural waypoint in mid-September. That review concerns case compliance; it is not a personal-injury settlement or a merits ruling.

The Hair Relaxer Products Liability Litigation (3060) led the day with 19 filings, up from 11. Keller Postman LLC filed five; Kline Specter PC, Peiffer Wolf, Singleton Schreiber LLP and Wallace Miller filed three each. The case-specific calendar now turns toward the Oct. 16 expert-discovery close and Nov. 16 deadline for summary-judgment and non-general-causation Daubert motions.

The Ozempic Products Liability Litigation (3094) added eight cases, up from three. Wagstaff & Cartmell LLP filed three, while Lieff Cabraser and Motley Rice filed two each. JPML's Aug. 3 report listed 3,928 actions pending before Judge Karen S. Marston. The court's cross-cutting expert track has moved beyond depositions into Rule 702 disputes over preemption and warning adequacy, along with general causation for gastroparesis, ileus, small-bowel obstruction and gallbladder injuries.

See the full filing feed and firm-level breakdowns here.

JAMA Update Narrows the Prenatal Acetaminophen Theory

On August 4, 2026, JAMA published a medical-news report stating that a new study adds to the evidence that acetaminophen use during pregnancy does not appear to cause autism or ADHD, sharpening the general-causation record in Acetaminophen - ASD/ADHD Products Liability Litigation (3043). The report places current medical commentary behind a conclusion that cuts against a direct prenatal-exposure theory. It does not resolve product liability or individualized causation, but it gives defendants a current source for challenging expert opinions that treat use during pregnancy as sufficient proof of neurodevelopmental injury. Plaintiffs will need to distinguish the evidence underlying any case-specific opinion from the broader causation question the report addresses.

NDMA Formation Study Adds an Alternative-Pathway Issue

On August 4, 2026, Environmental Science & Technology published research identifying a pathway for N-nitrosodimethylamine formation during nitrite electro-oxidation in water-treatment settings, adding a current nitrosamine record to Zantac Products Liability Litigation (2924). The researchers observed NDMA formation in a flow-through electrochemical cell and found that routine nitrite or chloride activity measures did not reliably predict nitrosamine yield. The study does not evaluate ranitidine, product stability, or any claimant's exposure, so it cannot establish product-specific causation in the litigation. Its immediate value is narrower: it gives counsel another current basis to scrutinize whether proposed NDMA measurements and exposure opinions adequately account for formation pathways outside the challenged drug.